Allen et al. demonstrated that the combination of anti-angiogenic therapy targeting VEGFR-2 and anti-PD-L1 immunotherapy resulted in improved efficacy in models of pancreatic neuroendocrine tumor (RT2-PNET), mammary carcinoma (MMTV-PyMT) and glioblastoma (NFpp10-GBM) [93,94]. This evidence concerns the gene KDR and glioblastoma.